Trevi Therapeutics has finished enrolling subjects in a trial of investigational Haduvio for treating chronic cough in IPF ...

Early results from the company’s single-arm trial saw the therapy able to partially repair the chemical responsible for ...

In an anonymous post in the BMJ, the author claims that words relating to DEI could lead to grants being taken away.

The CoTikiS trial’s 10-week results from the 50-week ulcerative colitis trial saw as an endoscopic improvement rate of 32% in ...

The Phase II trial comes as the US Food and Drug Administration grants an investigational new drug application for cannabis ...

Sanofi and Teva Pharmaceuticals have reported new outcomes from the Phase IIb RELIEVE UCCD trial of duvakitug.

Ensho has presented additional data supporting NSHO-101, also referred to as EA1080, as an oral one-time-a-day treatment for ...

NHS data showed a 40% increase in the detection of blood-borne infections, including HIV, during a pilot scheme in 2023.

Solid Biosciences’ gene therapy candidate for patients with DMD has elicited a 110% expression of the microdystrophin gene.

Novadip's bone graft material NVDX3 has seen all patients achieve bone fracture union in a 12-month Phase Ib/IIa ...

Vyne Therapeutics has dosed the first participant in a Phase Ib trial of VYN202, an oral treatment for moderate-to-severe ...

The Fragile X syndrome (FXS) market across the US and Germany is projected to grow at a CAGR of 14.7% from 2020 to 2030.